الصفحة 1
الصفحة 1
Human battle against obesity
Obesity is one of the most common preventable diseases and it is a medical condition in which excess fat has accumulated in the body, mostly in the subcutaneous tissues. Clinical obesity is considered to be present when a person has a body mass index of 30 or over. Obesity results from a chronic positive energy balance regulated by a complex interaction between endocrine tissues and the central nervous system, This activity reviews the pathophysiology of obesity, inflammatory markers secreted by excessive fat deposition in adipose tissue, and their effects on chronic diseases such as hypertension, diabetes, and dyslipidemia.
Graves' disease And New Therapies
• Thyroid gland. • The hypothalamic pituitary thyroid axis. • Thyroid hormones. • Physiology. • Thyroid tests. • Blood tests. • TSH test. • T4 tests. • T3 test. • Thyroid antibodies test. • Imaging tests. • Ultrasound. • Thyroid scan. • Radioactive iodine uptake test. • Thyroid gland disorders. • Hyperthyroidism. • Hypothyroidism. • Anti-thyroid medication. • Radioactive iodine therapy. • Thyroid surgery. • Graves’ ophthalmopathy. • Treatment of GO.
70 Years of Levothyroxine
Presents the history, pharmacokinetics and pharmacodynamics of levothyroxine, discussing its role in the thyroid pathophysiology of patients of various ages and during pregnancy. It also describes the influence of levothyroxine on heart, bone and in cancer. When it was first synthesized in 1949, levothyroxine represented a significant advance in the treatment of hypothyroidism, providing a safe and effective treatment option for millions of hypothyroid patients around the globe. This synthetic form of thyroxine is now one of the most prescribed drugs in the world. Levothyroxine was first introduced by Merck KGaA,Darmstadt, Germany, in 1972, and since then the company has remained actively engaged in research on this mainstay of hypothyroidism treatment.
